New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease [Yahoo! Finance]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Yahoo! Finance
leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease , which was recently published by the Kidney Disease Improving Global Outcomes (KDIGO) organization, a leading medical society in nephrology. The updated guideline includes consensus statements supporting the use of genetic testing to establish the cause of chronic kidney disease (CKD) for a majority of patients with this condition. The KDIGO guideline, specifically in Practice Points 1.1.4.1 and 1.1.4.2, states that genetic tests should be used, among other factors, to establish cause for CKD, and that genetic testing can impact the clinical management of people with CKD. The guideline also emphasizes that genetic causes may be present even without a family history; and it references six clinical scenarios, covering the majority of CKD patients, where genetic testing is particularly informative, including: Conditions with high preval
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera (NTRA) Rose on Momentum in the Oncology Market [Yahoo! Finance]Yahoo! Finance
- Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications [Yahoo! Finance]Yahoo! Finance
- Natera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsBusiness Wire
- Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $90.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
NTRA
Earnings
- 2/28/24 - Beat
NTRA
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/24/24 - Form ARS
- NTRA's page on the SEC website